Zydus Lifesciences subsidiary Sentynl Therapeutics has announced the worldwide acquisition of the Zokinvy (lonafarnib) programme from Eiger BioPharmaceuticals for the treatment of progeria.

Zokinvy is the first and only US FDA-approved treatment targeting the cause and symptoms of Progeria in young people above 12 months of age. Progeria, which encompasses Hutchinson-Gilford Progeria ...